Semaglutide paired with intensive behavioral therapy showed triple weight loss vs placebo
In study at Penn Medicine and other locations, participants lost an average of 16% of starting weight, more than one-third lost 20% or more of baseline weight
PHILADELPHIA -- A second study of the injectable anti-obesity medication, semaglutide, has confirmed the large weight losses reported in a study earlier this month, establishing the reliability and robustness of this new drug. With obesity affecting more than 40 percent of American adults, the findings could have a major impact on weight management in primary care and other settings. The END